<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T09:53:41Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10946757" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10946757</identifier>
        <datestamp>2024-03-19</datestamp>
        <setSpec>blackwellopen</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" id="jop13452" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">J Oral Pathol Med</journal-id>
              <journal-id journal-id-type="iso-abbrev">J Oral Pathol Med</journal-id>
              <journal-id journal-id-type="doi">10.1111/(ISSN)1600-0714</journal-id>
              <journal-id journal-id-type="publisher-id">JOP</journal-id>
              <journal-title-group>
                <journal-title>Journal of Oral Pathology &amp; Medicine</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0904-2512</issn>
              <issn pub-type="epub">1600-0714</issn>
              <publisher>
                <publisher-name>John Wiley and Sons Inc.</publisher-name>
                <publisher-loc>Hoboken</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10946757</article-id>
              <article-id pub-id-type="pmcid">PMC10946757</article-id>
              <article-id pub-id-type="pmc-uid">10946757</article-id>
              <article-id pub-id-type="pmid">37220073</article-id>
              <article-id pub-id-type="pmid">37220073</article-id>
              <article-id pub-id-type="doi">10.1111/jop.13452</article-id>
              <article-id pub-id-type="publisher-id">JOP13452</article-id>
              <article-categories>
                <subj-group subj-group-type="overline">
                  <subject>Original Article</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Original Articles</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Long‐term effectiveness of a novel intra‐oral electro‐stimulator for the treatment of dry mouth in patients with <styled-content style="fixed-case" toggle="no">Sjogren's</styled-content> syndrome: A randomised sham‐controlled feasibility study (<styled-content style="fixed-case" toggle="no">LEONIDAS</styled-content>‐1)</article-title>
                <alt-title alt-title-type="left-running-head">Fedele et al.</alt-title>
              </title-group>
              <contrib-group>
                <contrib id="jop13452-cr-0001" contrib-type="author" corresp="yes">
                  <name>
                    <surname>Fedele</surname>
                    <given-names>Stefano</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9006-9412</contrib-id>
                  <xref rid="jop13452-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="jop13452-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <address>
                    <email>s.fedele@ucl.ac.uk</email>
                  </address>
                </contrib>
                <contrib id="jop13452-cr-0002" contrib-type="author">
                  <name>
                    <surname>Al‐Hamad</surname>
                    <given-names>Arwa</given-names>
                  </name>
                  <xref rid="jop13452-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                  <xref rid="jop13452-aff-0004" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib id="jop13452-cr-0003" contrib-type="author">
                  <name>
                    <surname>Mercadante</surname>
                    <given-names>Valeria</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3164-854X</contrib-id>
                  <xref rid="jop13452-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="jop13452-cr-0004" contrib-type="author">
                  <name>
                    <surname>Porter</surname>
                    <given-names>Stephen</given-names>
                  </name>
                  <xref rid="jop13452-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="jop13452-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jop13452-cr-0005" contrib-type="author">
                  <name>
                    <surname>Isenberg</surname>
                    <given-names>David</given-names>
                  </name>
                  <xref rid="jop13452-aff-0005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib id="jop13452-cr-0006" contrib-type="author">
                  <name>
                    <surname>Poveda‐Gallego</surname>
                    <given-names>Ana</given-names>
                  </name>
                  <xref rid="jop13452-aff-0006" ref-type="aff">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib id="jop13452-cr-0007" contrib-type="author">
                  <name>
                    <surname>Brown</surname>
                    <given-names>Sarah T.</given-names>
                  </name>
                  <xref rid="jop13452-aff-0007" ref-type="aff">
                    <sup>7</sup>
                  </xref>
                </contrib>
              </contrib-group>
              <aff id="jop13452-aff-0001">
                <label>
                  <sup>1</sup>
                </label>
                <institution>UCL Eastman Dental Institute, University College London</institution>
                <city>London</city>
                <country country="GB">UK</country>
              </aff>
              <aff id="jop13452-aff-0002">
                <label>
                  <sup>2</sup>
                </label>
                <institution>NIHR UCLH Biomedical Research Centre</institution>
                <city>London</city>
                <country country="GB">UK</country>
              </aff>
              <aff id="jop13452-aff-0003">
                <label>
                  <sup>3</sup>
                </label>
                <named-content content-type="organisation-division">King Abdulaziz Medical City</named-content>
                <institution>National Guard Health Affairs</institution>
                <city>Riyadh</city>
                <country country="SA">Saudi Arabia</country>
              </aff>
              <aff id="jop13452-aff-0004">
                <label>
                  <sup>4</sup>
                </label>
                <named-content content-type="organisation-division">College of Dentistry</named-content>
                <institution>King Saud Bin Abdulaziz University for Health Sciences</institution>
                <city>Riyadh</city>
                <country country="SA">Saudi Arabia</country>
              </aff>
              <aff id="jop13452-aff-0005">
                <label>
                  <sup>5</sup>
                </label>
                <named-content content-type="organisation-division">Centre for Rheumatology, Division of Medicine</named-content>
                <institution>University College London</institution>
                <city>London</city>
                <country country="GB">UK</country>
              </aff>
              <aff id="jop13452-aff-0006">
                <label>
                  <sup>6</sup>
                </label>
                <named-content content-type="organisation-division">Oral Medicine</named-content>
                <institution>Birmingham Dental Hospital and School of Dentistry</institution>
                <city>Birmingham</city>
                <country country="GB">UK</country>
              </aff>
              <aff id="jop13452-aff-0007">
                <label>
                  <sup>7</sup>
                </label>
                <named-content content-type="organisation-division">Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research</named-content>
                <institution>University of Leeds</institution>
                <city>Leeds</city>
                <country country="GB">UK</country>
              </aff>
              <author-notes>
                <corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Stefano Fedele, Professor of Oral Medicine/Honorary Consultant in Oral Medicine &amp; Facial Pain, University College London, UCL Eastman Dental Institute, 21 University Street, London WC1E 6DE, UK.<break/>
Email: <email>s.fedele@ucl.ac.uk</email>
<break/>
</corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>23</day>
                <month>5</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <month>8</month>
                <year>2023</year>
              </pub-date>
              <volume>52</volume>
              <issue seq="80">7</issue>
              <issue-id pub-id-type="doi">10.1111/jop.v52.7</issue-id>
              <fpage>619</fpage>
              <lpage>627</lpage>
              <history>
                <date date-type="rev-recd">
                  <day>04</day>
                  <month>4</month>
                  <year>2023</year>
                </date>
                <date date-type="received">
                  <day>10</day>
                  <month>1</month>
                  <year>2023</year>
                </date>
                <date date-type="accepted">
                  <day>28</day>
                  <month>4</month>
                  <year>2023</year>
                </date>
              </history>
              <permissions>
                <!--&#x000a9; 2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.-->
                <copyright-statement content-type="article-copyright">© 2023 The Authors. <italic toggle="yes">Journal of Oral Pathology &amp; Medicine</italic> published by John Wiley &amp; Sons Ltd.</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="file:JOP-52-619.pdf"/>
              <abstract>
                <title>Abstract</title>
                <sec id="jop13452-sec-0001">
                  <title>Background</title>
                  <p>Effective treatments for dry mouth of Sjogren's syndrome are limited and hampered by adverse effects. The aim of LEONIDAS‐1 was to explore the feasibility of salivary electrostimulation in individuals with primary Sjogren's syndrome, as well as parameters required to inform the design of a future phase III trial.</p>
                </sec>
                <sec id="jop13452-sec-0002">
                  <title>Methods</title>
                  <p>Multicentre, parallel‐group, double‐blind, randomised sham‐controlled trial in two UK centres. Participants were randomised (1:1, computer‐generated) to active or sham electrostimulation. The feasibility outcomes included screening/eligibility ratio, consent, and recruitment and drop‐out rates. Preliminary efficacy outcome included dry mouth visual analogue scale, Xerostomia Inventory, the EULAR Sjögren's syndrome patient reported index‐Q1, and unstimulated sialometry.</p>
                </sec>
                <sec id="jop13452-sec-0003">
                  <title>Results</title>
                  <p>Forty‐two individuals were screened, of whom 30 (71.4%) met the eligibility criteria. All eligible individuals consented to recruitment. Out of the 30 randomised participants (active <italic toggle="no">n</italic> = 15, sham <italic toggle="no">n</italic> = 15), 4 dropped out and 26 (13 vs. 13) completed all study visits as per protocol. Recruitment rate was 2.73 participants/month. At 6‐month post‐randomisation the difference in mean reduction in visual analogue scale, xerostomia inventory and EULAR Sjögren's syndrome patient reported index‐Q1 scores between groups were 0.36 (95% CI: −0.84, 1.56), 3.31 (0.43, 6.18), and 0.23 (−1.17, 1.63), respectively; unstimulated salivary flow increased by a mean of 0.98 mL/15 min, all in favour of the active group. No adverse events were reported.</p>
                </sec>
                <sec id="jop13452-sec-0004">
                  <title>Conclusion</title>
                  <p>LEONIDAS‐1 results support progression to a phase III definitive randomised controlled trial of salivary electrostimulation in individuals with Sjogren's syndrome. Xerostomia inventory could be considered the primary patient‐centred outcome measure and the corresponding observed treatment effect could inform the sample size of a future trial.</p>
                </sec>
              </abstract>
              <kwd-group kwd-group-type="author-generated">
                <kwd id="jop13452-kwd-0001">salivary glands</kwd>
                <kwd id="jop13452-kwd-0002">whole unstimulated salivary flow rate</kwd>
              </kwd-group>
              <funding-group>
                <award-group id="funding-0001">
                  <funding-source>
                    <institution-wrap>
                      <institution>Arthritis Research UK
</institution>
                      <institution-id institution-id-type="doi">10.13039/501100000341</institution-id>
                    </institution-wrap>
                  </funding-source>
                </award-group>
                <award-group id="funding-0002">
                  <funding-source>NIHR Clinical Research Network North Thames</funding-source>
                </award-group>
                <award-group id="funding-0003">
                  <funding-source>NIHR UCLH Biomedical Research Centre</funding-source>
                </award-group>
              </funding-group>
              <counts>
                <fig-count count="2"/>
                <table-count count="4"/>
                <page-count count="9"/>
                <word-count count="5404"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>source-schema-version-number</meta-name>
                  <meta-value>2.0</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>cover-date</meta-name>
                  <meta-value>August 2023</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>details-of-publishers-convertor</meta-name>
                  <meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.3.9 mode:remove_FC converted:18.03.2024</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <p content-type="self-citation">
                <mixed-citation publication-type="journal" id="jop13452-cit-9001"><string-name><surname>Fedele</surname><given-names>S</given-names></string-name>, <string-name><surname>Al‐Hamad</surname><given-names>A</given-names></string-name>, <string-name><surname>Mercadante</surname><given-names>V</given-names></string-name>, et al. <article-title>Long‐term effectiveness of a novel intra‐oral electro‐stimulator for the treatment of dry mouth in patients with <styled-content style="fixed-case" toggle="no">Sjogren's</styled-content> syndrome: A randomised sham‐controlled feasibility study (<styled-content style="fixed-case" toggle="no">LEONIDAS</styled-content>‐1)</article-title>. <source>J Oral Pathol Med</source>. <year>2023</year>;<volume>52</volume>(<issue>7</issue>):<fpage>619</fpage>‐<lpage>627</lpage>. doi:<pub-id pub-id-type="doi">10.1111/jop.13452</pub-id>
<pub-id pub-id-type="pmid">37220073</pub-id>
</mixed-citation>
              </p>
            </notes>
          </front>
          <body id="jop13452-body-0001">
            <sec id="jop13452-sec-0005">
              <label>1</label>
              <title>INTRODUCTION</title>
              <p>Salivary gland hypofunction (dry mouth) is a cardinal feature of Sjogren's syndrome (SS).<xref rid="jop13452-bib-0001" ref-type="bibr"><sup>1</sup></xref> It is reported by the vast majority of SS patients (&gt;90%) and the first manifestation of the disease in more than half of cases (up to 54%),<xref rid="jop13452-bib-0002" ref-type="bibr"><sup>2</sup></xref> leading to a significant reduction in oral health‐related and general quality of life.<xref rid="jop13452-bib-0003" ref-type="bibr"><sup>3</sup></xref>, <xref rid="jop13452-bib-0004" ref-type="bibr"><sup>4</sup></xref>, <xref rid="jop13452-bib-0005" ref-type="bibr"><sup>5</sup></xref>, <xref rid="jop13452-bib-0006" ref-type="bibr"><sup>6</sup></xref> The treatment of salivary hypofunction of SS is a challenge for clinicians (summary of current evidence in Data <xref rid="jop13452-supitem-0001" ref-type="supplementary-material">S1</xref>).<xref rid="jop13452-bib-0007" ref-type="bibr"><sup>7</sup></xref>, <xref rid="jop13452-bib-0008" ref-type="bibr"><sup>8</sup></xref>, <xref rid="jop13452-bib-0009" ref-type="bibr"><sup>9</sup></xref>, <xref rid="jop13452-bib-0010" ref-type="bibr"><sup>10</sup></xref>, <xref rid="jop13452-bib-0011" ref-type="bibr"><sup>11</sup></xref>
</p>
              <p>Neuro‐electrostimulation of the parasympathetic and sympathetic autonomic nerve pathways regulating salivary secretion is considered an attractive non‐pharmacological intervention<xref rid="jop13452-bib-0012" ref-type="bibr"><sup>12</sup></xref>, <xref rid="jop13452-bib-0013" ref-type="bibr"><sup>13</sup></xref> that may potentially tackle the unmet need of an adverse effect‐free treatment of dry mouth of SS. However its effectiveness in the SS population is unclear. A meta‐analysis conducted in 2019 assessed two double‐blind randomised sham‐controlled studies<xref rid="jop13452-bib-0014" ref-type="bibr"><sup>14</sup></xref>, <xref rid="jop13452-bib-0015" ref-type="bibr"><sup>15</sup></xref> recruiting a total of 100 SS participants and reported an increase in unstimulated salivary flow associated with the use of a first‐generation intra‐oral electro‐stimulating device, although the quality of evidence was low.<xref rid="jop13452-bib-0009" ref-type="bibr"><sup>9</sup></xref> A subsequent multicentre study using a second‐generation custom‐made electro‐stimulating device (the same device as in LEONIDAS‐1) also reported a reduction in dry mouth symptoms and increased salivation<xref rid="jop13452-bib-0016" ref-type="bibr"><sup>16</sup></xref>, <xref rid="jop13452-bib-0017" ref-type="bibr"><sup>17</sup></xref>; however, the quality of evidence was again considered low.<xref rid="jop13452-bib-0009" ref-type="bibr"><sup>9</sup></xref> Hence, there remains currently little evidence regarding the clinical effectiveness of salivary neuro‐electrostimulation in individuals with SS. Further robust research in the form of a well‐designed long‐term multi‐centre randomised controlled trial (RCT) is needed to test the hypothesis that the application of an intra‐oral electro‐stimulating device can reduce dry mouth symptoms, increase salivary function, and improve quality of life.</p>
              <p>The aims of LEONIDAS‐1 (<italic toggle="yes">Long‐term effectiveness of a novel intra‐oral electro‐stimulator for the treatment of dry mouth in patients with Sjogren's Syndrome: a feasibility study</italic>) were to explore the feasibility and acceptability of salivary electrostimulation using a removable second‐generation custom‐made intra‐oral electro‐stimulating device in individuals with primary SS, as well as a number of study parameters needed to ensure the most appropriate design of a future phase III study including estimates of recruitment rate, compliance with the study intervention, and attrition. A further aim was to obtain preliminary data to quantify the ‘effect’ of the intra‐oral electro‐stimulating device upon dry mouth symptoms and salivary gland function to inform the sample size for a phase III study. The study is reported according to the CONSORT guidelines, extension to randomised pilot and feasibility trials.<xref rid="jop13452-bib-0018" ref-type="bibr"><sup>18</sup></xref>
</p>
            </sec>
            <sec sec-type="methods" id="jop13452-sec-0006">
              <label>2</label>
              <title>METHODS</title>
              <sec id="jop13452-sec-0007">
                <label>2.1</label>
                <title>Study design</title>
                <p>LEONIDAS‐1 was a multicentre, prospective, parallel group, double blind and randomised sham‐controlled trial, on patients with primary SS. Participants were randomised to receive 6 months of therapy with a removable active intra‐oral neuro‐electro‐stimulating device or a sham device (releasing tactile but not electrical stimulation). Participants were followed‐up at 1, 3 and 6 months, post‐randomisation. The subgroup of participants recruited at the lead study site were invited to attend a further standard of care hospital review at 12 months post‐randomisation (open‐label phase—6 months after suspending the study intervention).</p>
                <p>LEONIDAS‐1 received favourable opinion by the NRES Committee Yorkshire &amp; The Humber‐Sheffield (Reference: 11/YH/0423) and was sponsored by the Joint UCL/UCLH/Royal Free Biomedical Research Unit. Trial registration number was ISRCTN58887461. Participants provided written informed consent before trial‐related activities commenced.</p>
              </sec>
              <sec id="jop13452-sec-0008">
                <label>2.2</label>
                <title>Study Setting</title>
                <p>The study was undertaken in two clinical centres in the UK (outpatient clinics of the Oral Medicine and Rheumatology units of University College London Hospital [UCLH] and Birmingham Community Healthcare NHS Trust) by clinicians with expertise in the management of dry mouth of SS who regularly receive referrals from Rheumatology units and general medical and dental practitioners.</p>
              </sec>
              <sec id="jop13452-sec-0009">
                <label>2.3</label>
                <title>Participants</title>
                <p>The full list of study inclusion and exclusion criteria is presented in Table <xref rid="jop13452-tbl-0001" ref-type="table">1</xref>.<xref rid="jop13452-bib-0019" ref-type="bibr"><sup>19</sup></xref>
</p>
                <table-wrap position="float" id="jop13452-tbl-0001" content-type="TABLE">
                  <label>TABLE 1</label>
                  <caption>
                    <p>Study inclusion and exclusion criteria.</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col align="left" span="1"/>
                    <tbody valign="top">
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Inclusion criteria</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">
                          <list list-type="order" id="jop13452-list-0001">
                            <list-item id="jop13452-li-0001">
                              <p>≥18 years of age.</p>
                            </list-item>
                            <list-item id="jop13452-li-0002">
                              <p>Symptoms of xerostomia (dry mouth) due to primary SS syndrome diagnosed as per 2001 EU‐USA classification criteria.<xref rid="jop13452-bib-0019" ref-type="bibr"><sup>19</sup></xref>
</p>
                            </list-item>
                            <list-item id="jop13452-li-0003">
                              <p>A minimum degree of dry mouth symptoms of 50 mm (≥50 mm) on a 100 mm VAS scale (0 = no dryness; 100 = maximum dryness).</p>
                            </list-item>
                            <list-item id="jop13452-li-0004">
                              <p>No systemic sialogogue therapy (e.g., pilocarpine) for the duration of the study.</p>
                            </list-item>
                            <list-item id="jop13452-li-0005">
                              <p>Not be pregnant or trying to have children for the length of their participation. Female participants of child bearing potential would need to take measures to avoid pregnancy.</p>
                            </list-item>
                            <list-item id="jop13452-li-0006">
                              <p>To understand and consent in writing to the procedure.</p>
                            </list-item>
                            <list-item id="jop13452-li-0007">
                              <p>To agree to undergo all the examinations and clinical evaluations of the study.</p>
                            </list-item>
                            <list-item id="jop13452-li-0008">
                              <p>To have evidence of residual salivary gland function, by demonstrating an increase in salivary flow on appropriate stimulation (e.g., citric acid stimulation or chewing paraffin wax).</p>
                            </list-item>
                            <list-item id="jop13452-li-0009">
                              <p>To have unstimulated whole salivary flow higher than 0 mL/15 min (unstimulated salivary flow as measured via sialometry for 15 min).</p>
                            </list-item>
                          </list>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Exclusion criteria</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">
                          <list list-type="simple" id="jop13452-list-0002">
                            <list-item id="jop13452-li-0010">
                              <label>1</label>
                              <p>Severe systemic disease (on the basis of the classification of the American Society of Anesthesiology: ASAIII and ASA IV).</p>
                            </list-item>
                            <list-item id="jop13452-li-0011">
                              <label>2</label>
                              <p>Being pregnant or trying to have children.</p>
                            </list-item>
                            <list-item id="jop13452-li-0012">
                              <label>3</label>
                              <p>Known allergy to materials similar to those used in the investigational product.</p>
                            </list-item>
                            <list-item id="jop13452-li-0013">
                              <label>4</label>
                              <p>To wear other active implants such as cardiac pacemaker or defibrillator, or hearing aids.</p>
                            </list-item>
                            <list-item id="jop13452-li-0014">
                              <label>5</label>
                              <p>Complete lower edentulous status (i.e., no lower teeth).</p>
                            </list-item>
                            <list-item id="jop13452-li-0015">
                              <label>6</label>
                              <p>To have oral anatomical or disease‐related characteristics that preclude the insertion of the device (e.g., mandibular torus and severe trismus).</p>
                            </list-item>
                            <list-item id="jop13452-li-0016">
                              <label>1</label>
                              <p>To be unable or unwilling to cooperate with study procedures.</p>
                            </list-item>
                            <list-item id="jop13452-li-0017">
                              <label>2</label>
                              <p>To have evidence of no residual salivary gland function (via citric acid stimulation or chewing paraffin wax test).</p>
                            </list-item>
                            <list-item id="jop13452-li-0018">
                              <label>7</label>
                              <p>To have an unstimulated whole salivary flow = 0 mL/15 min (absence of unstimulated salivary flow as measured via sialometry for 15 min).</p>
                            </list-item>
                          </list>
                        </td>
                      </tr>
                    </tbody>
                  </table>
                </table-wrap>
              </sec>
              <sec id="jop13452-sec-0010">
                <label>2.4</label>
                <title>Intervention and Comparator</title>
                <sec id="jop13452-sec-0011">
                  <label>2.4.1</label>
                  <title>Active device</title>
                  <p>The device tested in LEONIDAS‐1 was a CE‐marked second‐generation removable custom‐made intra‐oral salivary neuro‐electrostimulator manufactured by Saliwell Ltd (Israel).</p>
                  <p>Further details of the electro‐stimulating device are provided in the Data <xref rid="jop13452-supitem-0001" ref-type="supplementary-material">S1</xref>. Participants were asked to use the device for a maximum of 5 min per hour, for as many times as they wanted during the day.</p>
                </sec>
                <sec id="jop13452-sec-0012">
                  <label>2.4.2</label>
                  <title>Sham device</title>
                  <p>The sham device's manufacturing and delivery process, as well as the appearance, was identical to the active device. However, the sham device did not deliver electric pulses.</p>
                </sec>
              </sec>
              <sec id="jop13452-sec-0013">
                <label>2.5</label>
                <title>Study procedures</title>
                <sec id="jop13452-sec-0014">
                  <label>2.5.1</label>
                  <title>Screening Visit</title>
                  <p>Potentially eligible participants were identified among patients with primary SS, provided with verbal and written information about the study, and invited to attend a screening visit for eligibility confirmation including the collection of unstimulated and stimulated sialometry and xerostomia visual analogue scale (VAS) score (details in the Data <xref rid="jop13452-supitem-0001" ref-type="supplementary-material">S1</xref>). Participants meeting the eligibility criteria had an impression of the lower dentition taken at the end of the screening visit, which was then sent to the device manufacturer. Demographic information was collected.</p>
                </sec>
                <sec id="jop13452-sec-0015">
                  <label>2.5.2</label>
                  <title>Randomisation</title>
                  <p>Participants were randomised in a 1:1 allocation ratio to active neuro‐electro‐stimulating device or a sham device. The randomisation sequence was computer‐generated using stratified random permuted blocks (block size 4), with stratification by centre. Participants were randomised via an independent and central service provided at the Leeds CTRU, to ensure allocation concealment. Further information is provided in the Data <xref rid="jop13452-supitem-0001" ref-type="supplementary-material">S1</xref>.</p>
                </sec>
                <sec id="jop13452-sec-0016">
                  <label>2.5.3</label>
                  <title>Blinding</title>
                  <p>The study was double‐blinded, with study investigators and participants unaware of the treatment group allocation.</p>
                </sec>
                <sec id="jop13452-sec-0017">
                  <label>2.5.4</label>
                  <title>Baseline visit</title>
                  <p>During the baseline visit, the allocated device was fitted and adjusted as needed so to ensure comfort and direct contact of the electrodes to the mandibular mucosa. The participants were instructed and trained regarding the modality of use of the device during the 6 months of the study. Written manufacturers' instructions were also provided.</p>
                  <p>Assessments conducted included dry mouth symptoms and salivary flow (see outcome measures below).</p>
                </sec>
                <sec id="jop13452-sec-0018">
                  <label>2.5.5</label>
                  <title>Follow‐up assessments at months 1, 3 and 6 post‐randomisation</title>
                  <p>The assessments were repeated at month 1, 3 and 6 post‐randomisation, with the visits running preferentially at the same time of the day as the baseline study visit so to minimise fluctuations related to the circadian rhythm of salivary secretion. Participants were also asked to complete a diary of the frequency of application of the device per day. Adverse events (harms) related to the intervention were monitored and recorded at study visits and any point in time as reported by the participants.</p>
                  <p>Saliva samples were collected during study visits and stored at −80°C for future mechanistic studies.</p>
                </sec>
                <sec id="jop13452-sec-0019">
                  <label>2.5.6</label>
                  <title>Study outcome measures</title>
                  <p>The feasibility outcome measures included screening/eligibility ratio, willingness of eligible patients to participate and be randomised into a double‐blind sham‐controlled trial (consent rate among eligible individuals), recruitment rate and acceptability of the intervention including withdrawal rate and frequency of use of the study device (number of applications). Preliminary efficacy primary outcome measures included dry mouth symptoms, evaluated through a 0–100 mm VAS<xref rid="jop13452-bib-0020" ref-type="bibr"><sup>20</sup></xref> and Xerostomia Inventory (XI),<xref rid="jop13452-bib-0021" ref-type="bibr"><sup>21</sup></xref> and main <italic toggle="yes">sicca</italic> symptoms of SS, measured using the EULAR Sjögren's syndrome patient reported index (ESSPRI‐Q1).<xref rid="jop13452-bib-0022" ref-type="bibr"><sup>22</sup></xref> Preliminary efficacy secondary outcomes included salivary flow, measured using unstimulated sialometry.<xref rid="jop13452-bib-0023" ref-type="bibr"><sup>23</sup></xref>
</p>
                </sec>
                <sec id="jop13452-sec-0020">
                  <label>2.5.7</label>
                  <title>Sample size</title>
                  <p>A sample size of 30 participants was pre‐specified, based on the recommendations for assessing feasibility outcomes and obtain preliminary estimates of response and variability.<xref rid="jop13452-bib-0024" ref-type="bibr"><sup>24</sup></xref> The target sample size was considered realistic based on the existing databases of SS patients at the study sites, as well as a contingency plan of contacting further potential participants on the UK Sjogren's syndrome registry.<xref rid="jop13452-bib-0025" ref-type="bibr"><sup>25</sup></xref>
</p>
                </sec>
              </sec>
              <sec id="jop13452-sec-0021">
                <label>2.6</label>
                <title>Statistical analysis</title>
                <p>The feasibility outcomes measures were summarised descriptively stratified by recruiting site and arm post‐randomisation. Summaries included the screening/eligibility ratio, consent rate, recruitment rate per month and acceptability of the intervention (withdrawals and device usage).</p>
                <p>Analysis of the efficacy outcomes was conducted on the complete case population, by randomised treatment group allocation. As this was a feasibility study, no formal tests were conducted, the focus being on estimation of the treatment effect and corresponding precision.</p>
                <p>Univariable linear regression was used to estimate the treatment effect on the change in score from baseline at 6 months post‐randomisation. Summary statistics for the reduction in scores at 6 months post‐baseline for the preliminary efficacy outcome measures, change in score for salivary flow and raw scores at each time point are presented by treatment group.</p>
                <p>Mean profiles over time (baseline, end of months 1, 3 and 6) are presented for the preliminary primary and secondary efficacy outcomes. Univariable linear regression was used to estimate the treatment effect on the reduction (or change as appropriate) in score from baseline to 6 months post‐randomisation. Corresponding difference in adjusted mean reduction (or change as appropriate) from baseline to 6 months are presented by treatment group.</p>
                <p>A pre‐planned exploratory analysis of VAS scores, XI and ESSPRI‐Q1 scores collected during the open‐label phase at 12 months post‐randomisation (6 months after suspending the study intervention) for the subgroup of participants at the lead recruiting site are reported as the difference in adjusted mean reduction from baseline and corresponding 95% CIs.</p>
              </sec>
              <sec id="jop13452-sec-0022">
                <label>2.7</label>
                <title>Role of funding sources</title>
                <p>Detailed in the Data <xref rid="jop13452-supitem-0001" ref-type="supplementary-material">S1</xref>.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="jop13452-sec-0023">
              <label>3</label>
              <title>RESULTS</title>
              <sec id="jop13452-sec-0024">
                <label>3.1</label>
                <title>Participant flow</title>
                <p>Between March 2012 and January 2013 potential participants were identified and approached during standard of care clinics at the two study sites. There was no requirement to use the UK Sjogren's Syndrome Registry due to achieving the target sample size. Forty‐two patients were screened, of whom 12 (28.6%) were excluded due to not meeting the eligibility criteria. The remaining 30 patients (71.4%) were eligible, and all gave written consent to participate in the trial, 25 at UCLH and 5 at Birmingham Community Healthcare NHS Trust. Fifteen (50%) were allocated to receive the active device, and 15 to receive the sham device (50%). The first participant was randomised on 24 April 2012, and the final participant on 22 January 2013. The participant flow is reported in the CONSORT flow diagram (Figure <xref rid="jop13452-fig-0001" ref-type="fig">1</xref>). Twenty‐six participants (86.6%) attended all the study visits as per protocol, 13 in each study arm. Four participants (two in the active device and two in the sham group) recruited at UCLH withdrew from all aspects of the study. There were no protocol deviations or violations reported. The baseline demographic and clinical characteristics for each group are presented in Table <xref rid="jop13452-tbl-0002" ref-type="table">2</xref>. The mean age of the participants recruited was 61.4 years (range: 44–79) and almost all were female (29/30, 96.7%). Most participants were of white ethnicity (27/30, 90%). Median (IQR) duration of SS at the point of recruitment was 6 years (2.8, 11.0) and baseline unstimulated salivary flow [mean (SD)] was 0.68 mL/15 min (0.74). The mean (SD) baseline scores for XI, dry mouth VAS and ESSPRI Q1 were 46.2 (6.38), 70.5 (1.61) and 8.3 (1.2), respectively. There were no notable differences between the study groups at baseline, except SS duration, which was longer in the sham group.</p>
                <fig position="float" fig-type="FIGURE" id="jop13452-fig-0001">
                  <label>FIGURE 1</label>
                  <caption>
                    <p>CONSORT flow chart.</p>
                  </caption>
                  <graphic xlink:href="JOP-52-619-g002" position="anchor" id="jats-graphic-1"/>
                </fig>
                <table-wrap position="float" id="jop13452-tbl-0002" content-type="TABLE">
                  <label>TABLE 2</label>
                  <caption>
                    <p>Baseline demographics and clinical characteristics.</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <thead valign="bottom">
                      <tr>
                        <th align="left" valign="bottom" rowspan="1" colspan="1"/>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Active device (<italic toggle="yes">n</italic> = 15)</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Sham device (<italic toggle="yes">n</italic> = 15)</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">All participants (<italic toggle="yes">n</italic> = 30)</th>
                      </tr>
                    </thead>
                    <tbody valign="top">
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Age (mean, range)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">61.4 (44, 79)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">61.8 (31, 82)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">61.6 (31, 82)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Female [<italic toggle="yes">n</italic>/<italic toggle="yes">n</italic> (%)]</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">15 (100%)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">14 (93.3%)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">29/30 (96.7%)</td>
                      </tr>
                      <tr>
                        <td rowspan="4" align="left" valign="top" colspan="1">Ethnicity [<italic toggle="yes">n</italic>/<italic toggle="yes">n</italic> (%)]</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">White 14 (93.3%)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">White 13 (86.7%)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">White 27 (90%)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Asian 1 (6.7%)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Asian 0 (0.0%)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Asian 1 (3.3%)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Black 0 (0.0%)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Black 1 (6.7%)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Black 1 (3.3%)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Other 0 (0.0%)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Other 1 (6.7%)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Other 1 (3.3%)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">SS duration (years) [median (IQR)]</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">3.0 (2.0, 14.0)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">7.0 (4.0, 10.0)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">6.0 (2.8, 11.0)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Unstimulated salivary flow (mL/15 min) [mean (SD)]</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.68 (0.61)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.69 (0.88)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.68 (0.74)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">XI score [mean (SD)]</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">47.3 (6.5)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">45.4 (6.1)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">46.2 (6.38)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Dry mouth 0–100 mm VAS [mean (SD)]</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">70.4 (1.8)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">70.5 (1.5)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">70.5 (1.61)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">ESSPRI‐Q1<xref rid="jop13452-note-0001" ref-type="table-fn"><sup>a</sup></xref> [mean (SD)]</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">8.4 (1.4)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">8.3 (1.1)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">8.3 (1.2)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="jop13452-ntgp-0002">
                    <fn id="jop13452-note-0001">
                      <label>
                        <sup>a</sup>
                      </label>
                      <p>ESSPRI‐Q1 data were collected only for participants recruited at UCLH.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="jop13452-sec-0025">
                <label>3.2</label>
                <title>Feasibility outcomes</title>
                <p>Overall screening/eligibility ratio was 42:30 (71.4% of the screened individuals were eligible across the two study sites). A ratio of 5:5 and 37:25 at Birmingham Community Healthcare NHS Trust and UCLH, respectively, was observed. All eligible patients consented to participation, therefore the ‘acceptability or willingness’ of eligible individuals to participate and be randomised into the study (consent rate) was 100%. The overall mean recruitment rate across both sites was 2.73 participants per month, corresponding to 30 participants recruited over 11 months. UCLH recruited 25 participants over 11 months (mean rate of 2.27/month) and Birmingham Community Healthcare NHS Trust recruited 5 participants over 5 months (mean rate of 1/month). A total of four participants (13.3%) withdrew from the study due to lack of compliance/no benefit perceived (<italic toggle="yes">n</italic> = 2, active arm), travelling (<italic toggle="yes">n</italic> = 1, sham arm), joined another trial (<italic toggle="yes">n</italic> = 1, sham arm). Among those participants who completed the trial, median use of the device was three times/day (range 0–11) in the active group and three times/day (range 0–10) in the sham group.</p>
              </sec>
              <sec id="jop13452-sec-0026">
                <label>3.3</label>
                <title>Preliminary efficacy outcomes</title>
                <p>A total of 26 participants (13 per treatment group) completed all study visits and therefore included in the preliminary efficacy primary and secondary outcome analyses. Data relevant to 21 participants at UCLH who attended the open‐label visit at 12 months post‐randomisation were included in the exploratory analyses. The mean profiles for each of the outcomes over time are presented in Figure <xref rid="jop13452-fig-0002" ref-type="fig">2A–C</xref>. Summary statistics are presented in Tables <xref rid="jop13452-tbl-0003" ref-type="table">3</xref> and <xref rid="jop13452-tbl-0004" ref-type="table">4</xref>.</p>
                <fig position="float" fig-type="FIGURE" id="jop13452-fig-0002">
                  <label>FIGURE 2</label>
                  <caption>
                    <p>Adjusted mean VAS score (A), XI (B), ESSPRI‐Q1 (C) and salivary flow (D) over 12 months by treatment group.</p>
                  </caption>
                  <graphic xlink:href="JOP-52-619-g001" position="anchor" id="jats-graphic-3"/>
                </fig>
                <table-wrap position="float" id="jop13452-tbl-0003" content-type="TABLE">
                  <label>TABLE 3</label>
                  <caption>
                    <p>Scores over time from baseline to 6 and 12 months by treatment group.</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <thead valign="bottom">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="bottom" rowspan="1" colspan="1"/>
                        <th align="left" valign="bottom" rowspan="1" colspan="1"/>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Baseline</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Month 1</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Month 3</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Month 6</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Month 12<xref rid="jop13452-note-0002" ref-type="table-fn"><sup>a</sup></xref>
</th>
                      </tr>
                    </thead>
                    <tbody valign="top">
                      <tr>
                        <td rowspan="2" align="left" valign="top" colspan="1">VAS</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Active</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">7.4 (1.8)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">6.8 (1.5)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">6.3 (2.3)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">6.9 (1.9)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">7.1 (2.5)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Sham</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">7.5 (1.5)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">7.7 (1.6)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">7.3 (2.0)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">7.3 (1.7)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">7.5 (2.8)</td>
                      </tr>
                      <tr>
                        <td rowspan="2" align="left" valign="top" colspan="1">XI</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Active</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">47.3 (6.5)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">45.5 (6.6)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">43.6 (7.1)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">43.5 (7.7)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">43.1 (6.6)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Sham</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">45.4 (6.1)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">44.9 (5.4)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">45.5 (6.6)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">45.3 (6.8)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">45.5 (7.7)</td>
                      </tr>
                      <tr>
                        <td rowspan="2" align="left" valign="top" colspan="1">ESSPRI‐Q1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Active</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">8.4 (1.4)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">7.6 (1.3)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">7.1 (1.5)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">7.2 (1.6)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">7.3 (1.9)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Sham</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">8.3 (1.1)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">7.2 (1.2)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">7.2 (1.4)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">7.3 (1.7)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">7.4 (2.3)</td>
                      </tr>
                      <tr>
                        <td rowspan="2" align="left" valign="top" colspan="1">Salivary flow (mL/15 min)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Active</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.7 (0.6)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1.1 (1.5)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1.4 (1.9)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1.9 (2.9)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">2.4 (3.8)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Sham</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.7 (0.9)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.6 (0.6)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.6 (0.5)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.8 (0.6)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.5 (0.6)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="jop13452-ntgp-0003">
                    <fn id="jop13452-note-0002">
                      <label>
                        <sup>a</sup>
                      </label>
                      <p>Data at 12 months were collected only for participants recruited at UCLH.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <table-wrap position="float" id="jop13452-tbl-0004" content-type="TABLE">
                  <label>TABLE 4</label>
                  <caption>
                    <p>Reduction (or change) in score at 6 months post‐baseline and overall difference.</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <thead valign="bottom">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="bottom" rowspan="1" colspan="1"/>
                        <th align="left" valign="bottom" rowspan="1" colspan="1"/>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Reduction at month 6 post‐baseline<xref rid="jop13452-note-0003" ref-type="table-fn"><sup>a</sup></xref>
</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Difference (95% CI)</th>
                      </tr>
                    </thead>
                    <tbody valign="top">
                      <tr>
                        <td rowspan="2" align="left" valign="top" colspan="1">VAS</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Active</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.7 (1.7)</td>
                        <td rowspan="2" align="left" valign="top" colspan="1">0.36 (−0.84, 1.56)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Sham</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.4 (1.3)</td>
                      </tr>
                      <tr>
                        <td rowspan="2" align="left" valign="top" colspan="1">XI</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Active</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">3.5 (4.1)</td>
                        <td rowspan="2" align="left" valign="top" colspan="1">3.31 (0.43, 6.18)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Sham</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.2 (3.0)</td>
                      </tr>
                      <tr>
                        <td rowspan="2" align="left" valign="top" colspan="1">ESSPRI‐Q1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Active</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1.3 (2.1)</td>
                        <td rowspan="2" align="left" valign="top" colspan="1">0.23 (−1.17, 1.63)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Sham</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1.1 (1.2)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table frame="hsides" rules="groups">
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <thead valign="bottom">
                      <tr>
                        <th align="left" valign="bottom" rowspan="1" colspan="1"/>
                        <th align="left" valign="bottom" rowspan="1" colspan="1"/>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Change at month 6 post‐baseline<xref rid="jop13452-note-0004" ref-type="table-fn"><sup>b</sup></xref>
</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Difference</th>
                      </tr>
                    </thead>
                    <tbody valign="top">
                      <tr>
                        <td rowspan="2" align="left" valign="top" colspan="1">Salivary flow (mL/15 min)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Active</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1.2 (2.5)</td>
                        <td rowspan="2" align="left" valign="top" colspan="1">0.98 (−0.48, 2.45)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Sham</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.2 (0.6)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="jop13452-ntgp-0004">
                    <fn id="jop13452-note-0003">
                      <label>
                        <sup>a</sup>
                      </label>
                      <p>Reduction defined as baseline score—month 6 score.</p>
                    </fn>
                    <fn id="jop13452-note-0004">
                      <label>
                        <sup>b</sup>
                      </label>
                      <p>Change defined as month 6 score—baseline score.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <sec id="jop13452-sec-0027">
                  <label>3.3.1</label>
                  <title>Primary outcomes</title>
                  <p>VAS scores: An initial reduction in mean VAS score in the active group was observed, however the mean VAS score in the sham group remained fairly constant over time. By 6 months post‐randomisation, the gap between treatment groups had almost closed (Figure <xref rid="jop13452-fig-0002" ref-type="fig">2</xref>). The difference in the mean reduction in VAS scores at 6 months post‐randomisation was 0.36 units (95% CI: −0.84, 1.56), with a greater reduction in the active group compared to the sham group.</p>
                  <p>XI scores: A greater reduction in XI score was observed in the active group than in the sham group (Figure <xref rid="jop13452-fig-0002" ref-type="fig">2B</xref>). At 6 months, the XI score reduced by a mean of 3.31 units more in the active group than in the sham group (95% CI 0.43, 6.18).</p>
                  <p>ESSPRI‐Q1: Little difference in <italic toggle="yes">sicca</italic> symptoms was observed between treatment groups; the corresponding difference in the mean reduction in dryness (ESSPRI‐Q1) at 6 months was 0.23 (95% CI: −1.17, 1.63). (Figure <xref rid="jop13452-fig-0002" ref-type="fig">2C</xref>).</p>
                </sec>
                <sec id="jop13452-sec-0028">
                  <label>3.3.2</label>
                  <title>Secondary outcome</title>
                  <p>A greater increase in salivary flow was observed in the active group compared to the sham group (Figure <xref rid="jop13452-fig-0002" ref-type="fig">2D</xref>). At 6 months post‐randomisation, salivary flow increased by a mean of 0.98 mL/15 min more in the active group than in the sham group (95% CI −0.48, 2.45).</p>
                </sec>
              </sec>
              <sec id="jop13452-sec-0029">
                <label>3.4</label>
                <title>Pre‐planned exploratory outcomes</title>
                <p>The mean scores for each of the exploratory outcomes at 12 months post‐randomisation (open‐label phase) are presented in Figure <xref rid="jop13452-fig-0002" ref-type="fig">2C</xref> and Table <xref rid="jop13452-tbl-0003" ref-type="table">3</xref>.</p>
                <p>VAS scores: the gap in VAS scores between treatment groups reduced by 12 months, with a corresponding difference in the mean reduction of 0.3 units (95% CI: −2.1, 2.8) (Figure <xref rid="jop13452-fig-0002" ref-type="fig">2</xref>).</p>
                <p>XI scores: a greater reduction in the mean XI score at 12 months was observed in the active compared to the sham group, with a corresponding difference between treatment groups of 4.2 (95% CI −0.04, 8.5) units (Figure <xref rid="jop13452-fig-0002" ref-type="fig">2B</xref>), suggesting that the reduction in XI score observed at 6 months was sustained at 12 months post‐randomisation.</p>
                <p>ESSPRI‐Q1 score: there was little difference observed in the reduction in dryness between treatment groups at 12 months, with a corresponding difference in ESSPRI‐Q1 score of 0.2 (95% CI: −1.8, 2.2) (Figure <xref rid="jop13452-fig-0002" ref-type="fig">2C</xref>).</p>
                <p>Salivary flow: an increase in salivary flow was observed in the active group at 12 months, with a mean increase of 1.7 g/15 min (95% CI −0.5 to 3.9) relative to the sham group (Figure <xref rid="jop13452-fig-0002" ref-type="fig">2D</xref>).</p>
              </sec>
              <sec id="jop13452-sec-0030">
                <label>3.5</label>
                <title>Related adverse event (harms)</title>
                <p>No adverse event (harm) related to the study intervention was reported by the participants or attending clinicians.</p>
              </sec>
            </sec>
            <sec sec-type="discussion" id="jop13452-sec-0031">
              <label>4</label>
              <title>DISCUSSION</title>
              <p>The screening/eligibility ratio, the consent rate and the recruitment rate observed in LEONIDAS‐1 provided convincing evidence that a future phase III definitive trial is likely to be feasible in NHS secondary care outpatient clinics that routinely care for SS patients. The acceptability of the intervention and the compliance with the study protocol was very good, with all eligible individuals consenting to recruitment, no reported protocol violation/deviations and a very small number of participants (4/30, 13.3%) withdrawing from the study. Of note, only two of these four participants withdrew from the study due to reasons related to the study intervention (no perceived benefit) or protocol (number of study visits), with no participant experiencing notable harm/adverse events. The demographics and clinical characteristics of the study participants at baseline were similar to those reported by other interventional studies in SS patients (e.g., TRACTISS),<xref rid="jop13452-bib-0026" ref-type="bibr"><sup>26</sup></xref> therefore suggesting that the LEONIDAS‐1 participants were a fairly representative of the wider SS population enrolled in clinical studies. Nonetheless, the fact that the majority of the participants were recruited at one site (25/30, 83.3%) may represent a potential source of selection bias and a generalisability concern with respect to feasibility and acceptability, suggesting that the future definitive trial would require multiple sites including PIC (patient identification centre) sites. We would also suggest that recruitment rates at both LEONIDAS‐1 sites (2.27/month vs. 1/month) should be considered to inform the expected recruitment rate in the future definitive trial.</p>
              <p>A further aim of LEONIDAS‐1 was to obtain data to preliminary assess the effect of the intervention on dry mouth symptoms and salivary gland function, with a view to inform the sample size of the future Phase III definitive trial and identify the outcome measure that is most likely to capture such effect. A preliminary assessment of the efficacy was also important to develop an evidence base to inform investigators and potential funders on the likely beneficial effect of the intervention and the value of a definitive multicentre phase III trial. The primary preliminary efficacy outcomes in LEONIDAS‐1 were all patient‐centred and included two validated measures for dry mouth (0–100 mm VAS and XI) and one validated patient‐reported sicca symptoms index (ESSPRI‐Q1). The secondary preliminary efficacy outcome was the unstimulated salivary flow. The study data showed a greater reduction in the XI score, suggesting that the electro‐stimulating device may effectively reduce dry mouth symptoms in individuals with SS. There was a further reduction in oral dryness as measured by the XI score in the subgroup of participants assessed at 12 months post‐randomisation (6 months after suspending the study intervention) in the pre‐planned exploratory analysis, suggesting a potential long‐term effect of the intervention. This is in keeping with the suggestion that neuro‐electrostimulation may have regenerative potential upon the salivary gland parenchyma.<xref rid="jop13452-bib-0027" ref-type="bibr"><sup>27</sup></xref>
</p>
              <p>A minimal, not fully convincing evidence of benefit was identified for the other patient‐centred outcomes or salivary flow, which is expected considering the small scale of this feasibility study not designed to demonstrate efficacy.</p>
            </sec>
            <sec sec-type="conclusions" id="jop13452-sec-0032">
              <label>5</label>
              <title>CONCLUSIONS</title>
              <p>LEONIDAS‐1 results support progression to a phase III definitive RCT of salivary electrostimulation in individuals with SS, on the basis of the results on feasibility, acceptability, lack of harm and preliminary evidence of efficacy upon dry mouth symptoms. In terms of informing the design of a future definitive trial, LEONIDAS‐1 results suggest that XI could be considered as the primary patient‐centred outcome measure as it was the most sensitive measure capturing the reduction in dry mouth symptoms. No notable major changes in the design, including the inclusion/exclusion criteria, would be considered necessary in the future trial, although it would be reasonable to consider a longer administration of the intervention (e.g., 12 months) to assess the longer term clinical effectiveness. The estimate of the observed treatment effect on the XI score could be used to inform the sample size calculation of a future phase III trial.</p>
            </sec>
            <sec id="jop13452-sec-0033">
              <title>AUTHOR CONTRIBUTIONS</title>
              <p><italic toggle="yes">Study design</italic>: Stefano Fedele and David Isenberg. <italic toggle="yes">Data collection</italic>: Stefano Fedele, Arwa Al‐Hamad, Valeria Mercadante, and Ana Poveda‐Gallego. <italic toggle="yes">Data analysis</italic>: Stefano Fedele, and Sarah T. Brown. <italic toggle="yes">Data interpretation</italic>: Stefano Fedele, Stephen Porter, David Isenberg, and Sarah T. Brown. <italic toggle="yes">Manuscript writing</italic>: Stefano Fedele. <italic toggle="yes">Manuscript Review and Editing</italic>: Arwa Al‐Hamad, Valeria Mercadante, Stephen Porter, David Isenberg, Ana Poveda‐Gallego, and Sarah T Brown. <italic toggle="yes">Study design</italic>: Stephen Porter.</p>
            </sec>
            <sec id="jop13452-sec-0035">
              <title>FUNDING INFORMATION</title>
              <p>Funding was provided by Arthritis Research UK (now renamed Versus Arthritis) (Reference 19 709), and further staff support was received from the NIHR Clinical Research Network North Thames and the NIHR UCLH Biomedical Research Centre. The funding source provided peer‐review for the study but had no other role in study design, collection, analysis, interpretation of data or writing of the report. The manufacturer Saliwell Ltd provided the study devices at reduced price for research purpose, and had no role in study design, collection, analysis, interpretation of data or writing of the report.</p>
            </sec>
            <sec sec-type="COI-statement" id="jop13452-sec-0036">
              <title>CONFLICT OF INTEREST STATEMENT</title>
              <p>None of the authors have a conflict of interest to disclose.</p>
            </sec>
            <sec id="jop13452-sec-0037">
              <sec disp-level="2" id="jop13452-sec-0039">
                <title>PEER REVIEW</title>
                <p>The peer review history for this article is available at <ext-link xlink:href="https://www.webofscience.com/api/gateway/wos/peer-review/10.1111/jop.13452" ext-link-type="uri">https://www.webofscience.com/api/gateway/wos/peer-review/10.1111/jop.13452</ext-link>.</p>
              </sec>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supporting information</title>
              <supplementary-material id="jop13452-supitem-0001" position="float" content-type="local-data">
                <caption>
                  <p><bold>Data S1.</bold> Supporting Information.</p>
                </caption>
                <media xlink:href="JOP-52-619-s001.docx"/>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack id="jop13452-sec-0034">
              <title>ACKNOWLEDGMENTS</title>
              <p>The authors are indebted to Professor Sue Pavitt and Janine Gray for their contribution to the design of Leonidas‐1, Professor Linda Sharples for contribution to the statistical analysis, and Professor John Hamburger for helping with patient recruitment.</p>
            </ack>
            <sec sec-type="data-availability" id="jop13452-sec-0038">
              <title>DATA AVAILABILITY STATEMENT</title>
              <p>The data that support the findings of this study are available from the corresponding author upon reasonable request.</p>
            </sec>
            <ref-list id="jop13452-bibl-0001" content-type="cited-references">
              <title>REFERENCES</title>
              <ref id="jop13452-bib-0001">
                <label>1</label>
                <mixed-citation publication-type="journal" id="jop13452-cit-0001"><string-name><surname>Fox</surname><given-names>RI</given-names></string-name>. <article-title>Sjögren's syndrome</article-title>. <source>Lancet</source>. <year>2005</year>;<volume>366</volume>(<issue>9482</issue>):<fpage>321</fpage>‐<lpage>331</lpage>.<pub-id pub-id-type="pmid">16039337</pub-id>
</mixed-citation>
              </ref>
              <ref id="jop13452-bib-0002">
                <label>2</label>
                <mixed-citation publication-type="journal" id="jop13452-cit-0002"><string-name><surname>Fox</surname><given-names>PC</given-names></string-name>, <string-name><surname>Bowman</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Segal</surname><given-names>B</given-names></string-name>, et al. <article-title>Oral involvement in primary Sjögren syndrome</article-title>. <source>J Am Dent Assoc</source>. <year>2008</year>;<volume>139</volume>(<issue>12</issue>):<fpage>1592</fpage>‐<lpage>1601</lpage>.<pub-id pub-id-type="pmid">19047665</pub-id>
</mixed-citation>
              </ref>
              <ref id="jop13452-bib-0003">
                <label>3</label>
                <mixed-citation publication-type="journal" id="jop13452-cit-0003"><string-name><surname>Carr</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Ng</surname><given-names>WF</given-names></string-name>, <string-name><surname>Figueiredo</surname><given-names>F</given-names></string-name>, <string-name><surname>Macleod</surname><given-names>RI</given-names></string-name>, <string-name><surname>Greenwood</surname><given-names>M</given-names></string-name>, <string-name><surname>Staines</surname><given-names>K</given-names></string-name>. <article-title>Sjögren's syndrome‐an update for dental practitioners</article-title>. <source>Br Dent J</source>. <year>2012</year>;<volume>213</volume>(<issue>7</issue>):<fpage>353</fpage>‐<lpage>357</lpage>.<pub-id pub-id-type="pmid">23059671</pub-id>
</mixed-citation>
              </ref>
              <ref id="jop13452-bib-0004">
                <label>4</label>
                <mixed-citation publication-type="journal" id="jop13452-cit-0004"><string-name><surname>López‐Jornet</surname><given-names>P</given-names></string-name>, <string-name><surname>Camacho‐Alonso</surname><given-names>F</given-names></string-name>. <article-title>Quality of life in patients with Sjögren's syndrome and sicca complex</article-title>. <source>J Oral Rehabil</source>. <year>2008</year>;<volume>35</volume>(<issue>12</issue>):<fpage>875</fpage>‐<lpage>881</lpage>.<pub-id pub-id-type="pmid">18976259</pub-id>
</mixed-citation>
              </ref>
              <ref id="jop13452-bib-0005">
                <label>5</label>
                <mixed-citation publication-type="journal" id="jop13452-cit-0005"><string-name><surname>Strömbeck</surname><given-names>B</given-names></string-name>, <string-name><surname>Ekdahl</surname><given-names>C</given-names></string-name>, <string-name><surname>Manthorpe</surname><given-names>R</given-names></string-name>, <string-name><surname>Wikström</surname><given-names>I</given-names></string-name>, <string-name><surname>Jacobsson</surname><given-names>L</given-names></string-name>. <article-title>Health‐related quality of life in primary Sjögren's syndrome, rheumatoid arthritis and fibromyalgia compared to normal population data using SF‐36</article-title>. <source>Scand J Rheumatol</source>. <year>2000</year>;<volume>29</volume>(<issue>1</issue>):<fpage>20</fpage>‐<lpage>28</lpage>.<pub-id pub-id-type="pmid">10722254</pub-id>
</mixed-citation>
              </ref>
              <ref id="jop13452-bib-0006">
                <label>6</label>
                <mixed-citation publication-type="journal" id="jop13452-cit-0006"><string-name><surname>Sutcliffe</surname><given-names>N</given-names></string-name>, <string-name><surname>Stoll</surname><given-names>T</given-names></string-name>, <string-name><surname>Pyke</surname><given-names>S</given-names></string-name>, <string-name><surname>Isenberg</surname><given-names>DA</given-names></string-name>. <article-title>Functional disability and end organ damage in patients with systemic lupus erythematosus (SLE), SLE and Sjögren's syndrome (SS), and primary SS</article-title>. <source>J Rheumatol</source>. <year>1998</year>;<volume>25</volume>(<issue>1</issue>):<fpage>63</fpage>‐<lpage>68</lpage>.<pub-id pub-id-type="pmid">9458204</pub-id>
</mixed-citation>
              </ref>
              <ref id="jop13452-bib-0007">
                <label>7</label>
                <mixed-citation publication-type="journal" id="jop13452-cit-0007"><string-name><surname>Montgomery‐Cranny</surname><given-names>J</given-names></string-name>, <string-name><surname>Hodgson</surname><given-names>T</given-names></string-name>, <string-name><surname>Hegarty</surname><given-names>AM</given-names></string-name>. <article-title>Aetiology and management of xerostomia and salivary gland hypofunction</article-title>. <source>Br J Hosp Med (Lond)</source>. <year>2014</year>;<volume>75</volume>(<issue>9</issue>):<fpage>509</fpage>‐<lpage>514</lpage>.<pub-id pub-id-type="pmid">25216167</pub-id>
</mixed-citation>
              </ref>
              <ref id="jop13452-bib-0008">
                <label>8</label>
                <mixed-citation publication-type="journal" id="jop13452-cit-0008"><string-name><surname>Saraux</surname><given-names>A</given-names></string-name>, <string-name><surname>Pers</surname><given-names>JO</given-names></string-name>, <string-name><surname>Devauchelle‐Pensec</surname><given-names>V</given-names></string-name>. <article-title>Treatment of primary Sjögren syndrome</article-title>. <source>Nat Rev Rheumatol</source>. <year>2016</year>;<volume>12</volume>(<issue>8</issue>):<fpage>456</fpage>‐<lpage>471</lpage>.<pub-id pub-id-type="pmid">27411907</pub-id>
</mixed-citation>
              </ref>
              <ref id="jop13452-bib-0009">
                <label>9</label>
                <mixed-citation publication-type="journal" id="jop13452-cit-0009"><string-name><surname>Al Hamad</surname><given-names>A</given-names></string-name>, <string-name><surname>Lodi</surname><given-names>G</given-names></string-name>, <string-name><surname>Porter</surname><given-names>S</given-names></string-name>, <string-name><surname>Fedele</surname><given-names>S</given-names></string-name>, <string-name><surname>Mercadante</surname><given-names>V</given-names></string-name>. <article-title>Interventions for dry mouth and hyposalivation in Sjögren's syndrome: a systematic review and meta‐analysis</article-title>. <source>Oral Dis</source>. <year>2019</year>;<volume>25</volume>(<issue>4</issue>):<fpage>1027</fpage>‐<lpage>1047</lpage>.<pub-id pub-id-type="pmid">30086205</pub-id>
</mixed-citation>
              </ref>
              <ref id="jop13452-bib-0010">
                <label>10</label>
                <mixed-citation publication-type="journal" id="jop13452-cit-0010"><string-name><surname>Cassolato</surname><given-names>SF</given-names></string-name>, <string-name><surname>Turnbull</surname><given-names>RS</given-names></string-name>. <article-title>Xerostomia: clinical aspects and treatment</article-title>. <source>Gerodontology</source>. <year>2003</year>;<volume>20</volume>(<issue>2</issue>):<fpage>64</fpage>‐<lpage>77</lpage>.<pub-id pub-id-type="pmid">14697016</pub-id>
</mixed-citation>
              </ref>
              <ref id="jop13452-bib-0011">
                <label>11</label>
                <mixed-citation publication-type="journal" id="jop13452-cit-0011"><string-name><surname>Ramos‐Casals</surname><given-names>M</given-names></string-name>, <string-name><surname>Brito‐Zerón</surname><given-names>P</given-names></string-name>. <article-title>Emerging biological therapies in primary Sjogren's syndrome</article-title>. <source>Rheumatology (Oxford)</source>. <year>2007</year>;<volume>46</volume>(<issue>9</issue>):<fpage>1389</fpage>‐<lpage>1396</lpage>.<pub-id pub-id-type="pmid">17586555</pub-id>
</mixed-citation>
              </ref>
              <ref id="jop13452-bib-0012">
                <label>12</label>
                <mixed-citation publication-type="journal" id="jop13452-cit-0012"><string-name><surname>Proctor</surname><given-names>GB</given-names></string-name>, <string-name><surname>Carpenter</surname><given-names>GH</given-names></string-name>. <article-title>Regulation of salivary gland function by autonomic nerves</article-title>. <source>Auton Neurosci</source>. <year>2007</year>;<volume>133</volume>(<issue>1</issue>):<fpage>3</fpage>‐<lpage>18</lpage>.<pub-id pub-id-type="pmid">17157080</pub-id>
</mixed-citation>
              </ref>
              <ref id="jop13452-bib-0013">
                <label>13</label>
                <mixed-citation publication-type="journal" id="jop13452-cit-0013"><string-name><surname>Izumi</surname><given-names>H</given-names></string-name>, <string-name><surname>Karita</surname><given-names>K</given-names></string-name>. <article-title>Low‐frequency subthreshold sympathetic stimulation augments maximal reflex parasympathetic salivary secretion in cats</article-title>. <source>Am J Physiol</source>. <year>1995</year>;<volume>268</volume>(<issue>5</issue>):<fpage>R1188</fpage>‐<lpage>R1195</lpage>.<pub-id pub-id-type="pmid">7771578</pub-id>
</mixed-citation>
              </ref>
              <ref id="jop13452-bib-0014">
                <label>14</label>
                <mixed-citation publication-type="journal" id="jop13452-cit-0014"><string-name><surname>Steller</surname><given-names>M</given-names></string-name>, <string-name><surname>Chou</surname><given-names>L</given-names></string-name>, <string-name><surname>Daniels</surname><given-names>TE</given-names></string-name>. <article-title>Electrical stimulation of salivary flow in patients with Sjögren's syndrome</article-title>. <source>J Dent Res</source>. <year>1988</year>;<volume>67</volume>(<issue>10</issue>):<fpage>1334</fpage>‐<lpage>1337</lpage>.<pub-id pub-id-type="pmid">3262637</pub-id>
</mixed-citation>
              </ref>
              <ref id="jop13452-bib-0015">
                <label>15</label>
                <mixed-citation publication-type="journal" id="jop13452-cit-0015"><string-name><surname>Talal</surname><given-names>N</given-names></string-name>, <string-name><surname>Quinn</surname><given-names>JH</given-names></string-name>, <string-name><surname>Daniels</surname><given-names>TE</given-names></string-name>. <article-title>The clinical effects of electrostimulation on salivary function of Sjögren's syndrome patients. A Placebo Controlled Study</article-title>. <source>Rheumatol Int</source>. <year>1992</year>;<volume>12</volume>(<issue>2</issue>):<fpage>43</fpage>‐<lpage>45</lpage>.<pub-id pub-id-type="pmid">1411081</pub-id>
</mixed-citation>
              </ref>
              <ref id="jop13452-bib-0016">
                <label>16</label>
                <mixed-citation publication-type="journal" id="jop13452-cit-0016"><string-name><surname>Strietzel</surname><given-names>FP</given-names></string-name>, <string-name><surname>Lafaurie</surname><given-names>GI</given-names></string-name>, <string-name><surname>Mendoza</surname><given-names>GR</given-names></string-name>, et al. <article-title>Efficacy and safety of an intraoral electrostimulation device for xerostomia relief: a multicenter, randomized trial</article-title>. <source>Arthritis Rheum</source>. <year>2011</year>;<volume>63</volume>(<issue>1</issue>):<fpage>180</fpage>‐<lpage>190</lpage>.<pub-id pub-id-type="pmid">20882668</pub-id>
</mixed-citation>
              </ref>
              <ref id="jop13452-bib-0017">
                <label>17</label>
                <mixed-citation publication-type="journal" id="jop13452-cit-0017"><string-name><surname>Alajbeg</surname><given-names>I</given-names></string-name>, <string-name><surname>Falcão</surname><given-names>DP</given-names></string-name>, <string-name><surname>Tran</surname><given-names>SD</given-names></string-name>, et al. <article-title>Intraoral electrostimulator for xerostomia relief: a long‐term, multicenter, open‐label, uncontrolled, clinical trial</article-title>. <source>Oral Surg Oral Med Oral Pathol Oral Radiol</source>. <year>2012</year>;<volume>113</volume>(<issue>6</issue>):<fpage>773</fpage>‐<lpage>781</lpage>.<pub-id pub-id-type="pmid">22668705</pub-id>
</mixed-citation>
              </ref>
              <ref id="jop13452-bib-0018">
                <label>18</label>
                <mixed-citation publication-type="journal" id="jop13452-cit-0018"><string-name><surname>Eldridge</surname><given-names>SM</given-names></string-name>, <string-name><surname>Chan</surname><given-names>CL</given-names></string-name>, <string-name><surname>Campbell</surname><given-names>MJ</given-names></string-name>, et al. <article-title>CONSORT 2010 statement: extension to randomised pilot and feasibility trials</article-title>. <source>BMJ</source>. <year>2016</year>;<volume>355</volume>:<elocation-id>i5239</elocation-id>.<pub-id pub-id-type="pmid">27777223</pub-id></mixed-citation>
              </ref>
              <ref id="jop13452-bib-0019">
                <label>19</label>
                <mixed-citation publication-type="journal" id="jop13452-cit-0019"><string-name><surname>Vitali</surname><given-names>C</given-names></string-name>, <string-name><surname>Bombardieri</surname><given-names>S</given-names></string-name>, <string-name><surname>Jonsson</surname><given-names>R</given-names></string-name>, et al. <article-title>Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American‐European consensus group</article-title>. <source>Ann Rheum Dis</source>. <year>2002</year>;<volume>61</volume>(<issue>6</issue>):<fpage>554</fpage>‐<lpage>558</lpage>.<pub-id pub-id-type="pmid">12006334</pub-id>
</mixed-citation>
              </ref>
              <ref id="jop13452-bib-0020">
                <label>20</label>
                <mixed-citation publication-type="journal" id="jop13452-cit-0020"><string-name><surname>Pai</surname><given-names>S</given-names></string-name>, <string-name><surname>Ghezzi</surname><given-names>EM</given-names></string-name>, <string-name><surname>Ship</surname><given-names>JA</given-names></string-name>. <article-title>Development of a visual analogue scale questionnaire for subjective assessment of salivary dysfunction</article-title>. <source>Oral Surg Oral Med Oral Pathol Oral Radiol Endod</source>. <year>2001</year>;<volume>91</volume>(<issue>3</issue>):<fpage>311</fpage>‐<lpage>316</lpage>.<pub-id pub-id-type="pmid">11250628</pub-id>
</mixed-citation>
              </ref>
              <ref id="jop13452-bib-0021">
                <label>21</label>
                <mixed-citation publication-type="journal" id="jop13452-cit-0021"><string-name><surname>Thomson</surname><given-names>WM</given-names></string-name>, <string-name><surname>Chalmers</surname><given-names>JM</given-names></string-name>, <string-name><surname>Spencer</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Williams</surname><given-names>SM</given-names></string-name>. <article-title>The xerostomia inventory: a multi‐item approach to measuring dry mouth</article-title>. <source>Community Dent Health</source>. <year>1999</year>;<volume>16</volume>(<issue>1</issue>):<fpage>12</fpage>‐<lpage>17</lpage>.<pub-id pub-id-type="pmid">10697349</pub-id>
</mixed-citation>
              </ref>
              <ref id="jop13452-bib-0022">
                <label>22</label>
                <mixed-citation publication-type="journal" id="jop13452-cit-0022"><string-name><surname>Seror</surname><given-names>R</given-names></string-name>, <string-name><surname>Ravaud</surname><given-names>P</given-names></string-name>, <string-name><surname>Mariette</surname><given-names>X</given-names></string-name>, et al. <article-title>EULAR Sjogren's syndrome patient reported index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome</article-title>. <source>Ann Rheum Dis</source>. <year>2011</year>;<volume>70</volume>(<issue>6</issue>):<fpage>968</fpage>‐<lpage>972</lpage>.<pub-id pub-id-type="pmid">21345815</pub-id>
</mixed-citation>
              </ref>
              <ref id="jop13452-bib-0023">
                <label>23</label>
                <mixed-citation publication-type="journal" id="jop13452-cit-0023"><string-name><surname>Heintze</surname><given-names>U</given-names></string-name>, <string-name><surname>Birkhed</surname><given-names>D</given-names></string-name>, <string-name><surname>Björn</surname><given-names>H</given-names></string-name>. <article-title>Secretion rate and buffer effect of resting and stimulated whole saliva as a function of age and sex</article-title>. <source>Swed Dent J</source>. <year>1983</year>;<volume>7</volume>(<issue>6</issue>):<fpage>227</fpage>‐<lpage>238</lpage>.<pub-id pub-id-type="pmid">6583873</pub-id>
</mixed-citation>
              </ref>
              <ref id="jop13452-bib-0024">
                <label>24</label>
                <mixed-citation publication-type="journal" id="jop13452-cit-0024"><string-name><surname>Lancaster</surname><given-names>GA</given-names></string-name>, <string-name><surname>Dodd</surname><given-names>S</given-names></string-name>, <string-name><surname>Williamson</surname><given-names>PR</given-names></string-name>. <article-title>Design and analysis of pilot studies: recommendations for good practice</article-title>. <source>J Eval Clin Pract</source>. <year>2004</year>;<volume>10</volume>(<issue>2</issue>):<fpage>307</fpage>‐<lpage>312</lpage>.<pub-id pub-id-type="pmid">15189396</pub-id>
</mixed-citation>
              </ref>
              <ref id="jop13452-bib-0025">
                <label>25</label>
                <mixed-citation publication-type="journal" id="jop13452-cit-0025"><string-name><surname>Ng</surname><given-names>WF</given-names></string-name>, <string-name><surname>Bowman</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Griffiths</surname><given-names>B</given-names></string-name>, <collab collab-type="authors">UKPSSR study group</collab>
. <article-title>United Kingdom primary Sjogren's syndrome registry‐a united effort to tackle an orphan rheumatic disease</article-title>. <source>Rheumatology (Oxford)</source>. <year>2011</year>;<volume>50</volume>(<issue>1</issue>):<fpage>32</fpage>‐<lpage>39</lpage>.<pub-id pub-id-type="pmid">20693261</pub-id>
</mixed-citation>
              </ref>
              <ref id="jop13452-bib-0026">
                <label>26</label>
                <mixed-citation publication-type="journal" id="jop13452-cit-0026"><string-name><surname>Fisher</surname><given-names>BA</given-names></string-name>, <string-name><surname>Everett</surname><given-names>CC</given-names></string-name>, <string-name><surname>Rout</surname><given-names>J</given-names></string-name>, et al. <article-title>Effect of rituximab on a salivary gland ultrasound score in primary Sjögren's syndrome: results of the TRACTISS randomised double‐blind multicentre substudy</article-title>. <source>Ann Rheum Dis</source>. <year>2018</year>;<volume>77</volume>(<issue>3</issue>):<fpage>412</fpage>‐<lpage>416</lpage>.<pub-id pub-id-type="pmid">29275334</pub-id>
</mixed-citation>
              </ref>
              <ref id="jop13452-bib-0027">
                <label>27</label>
                <mixed-citation publication-type="journal" id="jop13452-cit-0027"><string-name><surname>Wolff</surname><given-names>A</given-names></string-name>, <string-name><surname>Koray</surname><given-names>M</given-names></string-name>, <string-name><surname>Campisi</surname><given-names>G</given-names></string-name>, et al. <article-title>Electrostimulation of the lingual nerve by an intraoral device may lead to salivary gland regeneration: a case series study</article-title>. <source>Med Oral Patol Oral Cir Bucal</source>. <year>2018</year>;<volume>23</volume>(<issue>5</issue>):<fpage>e552</fpage>‐<lpage>e559</lpage>.<pub-id pub-id-type="pmid">30148471</pub-id>
</mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
